Table 2.
Malignancy Risk of Thyroid Nodules Assessed by the Bethesda Classification
| Total (n=200) | Benign (n=86) | Malignancy (n=114) | Recommended malignancy risk, % | |
|---|---|---|---|---|
| Bethesda category | ||||
| I (non-diagnostic) | 8 (4.0) | 6 (75.0) | 2 (25.0) | 1–4 |
| II (benign) | 34 (17.0) | 33 (97.1) | 1 (2.9) | 0–3 |
| III (AUS/FLUS) | 49 (24.5) | 36 (73.5) | 13 (26.5) | 5–15 |
| Cytologic atypia | 32 | 20 (62.5) | 12 (37.5) | - |
| Architectural atypia | 10 | 9 (90.0) | 1 (10.0) | - |
| Hurthle cell atypia | 7 | 7 (100.0) | 0 | - |
| IV (FN/SFN) | 7 (3.5) | 5 (71.4) | 2 (28.6) | 15–30 |
| V (suspicious for malignancy) | 22 (11.0) | 4 (18.2) | 18 (81.8) | 60–75 |
| VI (malignant) | 80 (40.0) | 2 (2.5) | 78 (97.5) | 97–99 |
Values are expressed as number (%). P value for benign vs. malignant nodules.
AUS/FLUS, atypia of undetermined significance or follicular lesion of undetermined significance; FN/SFN, follicular neoplasm or suspicious for a follicular neoplasm.